| ROLAPITANT HYDROCHLORIDE | None | ||
| 90MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| VARUBI is a substance P/neurokinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. | |||
|
Yes
| |||
| VARUBI | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 |
|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||
| *** *********** | ************** ************: ***** ** *-[{*-(*,*-***-(***************)******)-******}-******]-*-******-*,*-*****-*****[*.*]*****-*-*** *** ********* ******* ***** *** **** | ************** ************: ***** ** *-[{*-(*,*-***-(***************)******)-******}-******]-*-******-*,*-*****-*****[*.*]*****-*-*** *** ********* ******* ***** *** **** | ************* ***** ** *-[{*-(*,*-***-(***************)******)-******)-******]-*-******-*,*-*****-*****[*.*]*****-*-*** *** *********** ******* ******** | ****** ************ ********** *-[{*-(*,*-***-(***************)******)-******}-******]-*-******-*,*-*****-*****[*.*]*****-*-*** ***** *** ******* **** ********* | ************** ************:***** ** *-[*-*,*-***-(***************)******)-************]-*-******-*,*-*****-*****[*.*]*****-*-*** *** ********* ******* ***** *** **** | ************* ***** ** *-[{*-(*,*-***-***************)******)-******}-******]-*-******-*,*-*****-*****[*.*]*****-*-*** *** *********** ******* ******** | *** *********** | ****** ** ******* * ******* **** ** * ************* ****** |
| ROLAPITANT HYDROCHLORIDE | None | ||
| 166.5MG/92.5ML |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| VARUBI is a substance P/neurokinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. | |||
|
Yes
| |||
| VARUBI | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 |
|---|---|---|---|---|---|---|---|
| *** ********* | |||||||
| *** *********** | ************** ************: ***** ** *-[{*-(*,*-***-(***************)******)-******}-******]-*-******-*,*-*****-*****[*.*]*****-*-*** *** ********* ******* ***** *** **** | ************* ***** ** *-[{*-(*,*-***-(***************)******)-******)-******]-*-******-*,*-*****-*****[*.*]*****-*-*** *** *********** ******* ******** | ************** ************:***** ** *-[*-*,*-***-(***************)******)-************]-*-******-*,*-*****-*****[*.*]*****-*-*** *** ********* ******* ***** *** **** | ************* ***** ** *-[{*-(*,*-***-***************)******)-******}-******]-*-******-*,*-*****-*****[*.*]*****-*-*** *** *********** ******* ******** | *********** ************ ** **********-* *********** | *** *********** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|